| Orally absorbed cyclic peptides DS Nielsen, NE Shepherd, W Xu, AJ Lucke, MJ Stoermer, DP Fairlie Chemical reviews 117 (12), 8094-8128, 2017 | 362 | 2017 |
| Binding interaction of quercetin-3-β-galactoside and its synthetic derivatives with SARS-CoV 3CLpro: Structure–activity relationship studies reveal salient pharmacophore features L Chen, J Li, C Luo, H Liu, W Xu, G Chen, OW Liew, W Zhu, CM Puah, ... Bioorganic & medicinal chemistry 14 (24), 8295-8306, 2006 | 338 | 2006 |
| Drugs and drug-like molecules can modulate the function of mucosal-associated invariant T cells AN Keller, SBG Eckle, W Xu, L Liu, VA Hughes, JYW Mak, BS Meehan, ... Nature immunology 18 (4), 402-411, 2017 | 217 | 2017 |
| Stabilizing short-lived Schiff base derivatives of 5-aminouracils that activate mucosal-associated invariant T cells JYW Mak, W Xu, RC Reid, AJ Corbett, BS Meehan, H Wang, Z Chen, ... Nature communications 8 (1), 14599, 2017 | 134 | 2017 |
| Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth MJ Chua, MSJ Arnold, W Xu, J Lancelot, S Lamotte, GF Späth, E Prina, ... International Journal for Parasitology: Drugs and Drug Resistance 7 (1), 42-50, 2017 | 106 | 2017 |
| Potent cationic inhibitors of West Nile virus NS2B/NS3 protease with serum stability, cell permeability and antiviral activity MJ Stoermer, KJ Chappell, S Liebscher, CM Jensen, CH Gan, PK Gupta, ... Journal of medicinal chemistry 51 (18), 5714-5721, 2008 | 95 | 2008 |
| Discovery of novel small molecule inhibitors of dengue viral NS2B-NS3 protease using virtual screening and scaffold hopping J Deng, N Li, H Liu, Z Zuo, OW Liew, W Xu, G Chen, X Tong, W Tang, ... Journal of medicinal chemistry 55 (14), 6278-6293, 2012 | 87 | 2012 |
| Comparing sixteen scoring functions for predicting biological activities of ligands for protein targets W Xu, AJ Lucke, DP Fairlie Journal of Molecular Graphics and Modelling 57, 76-88, 2015 | 75 | 2015 |
| A potent antagonist of protease-activated receptor 2 that inhibits multiple signaling functions in human cancer cells Y Jiang, MK Yau, J Lim, KC Wu, W Xu, JY Suen, DP Fairlie Journal of Pharmacology and Experimental Therapeutics 364 (2), 246-257, 2018 | 61 | 2018 |
| The molecular basis underpinning the potency and specificity of MAIT cell antigens W Awad, GJM Ler, W Xu, AN Keller, JYW Mak, XY Lim, L Liu, SBG Eckle, ... Nature immunology 21 (4), 400-411, 2020 | 55 | 2020 |
| Class IIa histone deacetylases drive toll-like receptor-inducible glycolysis and macrophage inflammatory responses via pyruvate kinase M2 KD Gupta, MR Shakespear, JEB Curson, AMV Murthy, A Iyer, MP Hodson, ... Cell reports 30 (8), 2712-2728. e8, 2020 | 54 | 2020 |
| Receptor residence time trumps drug-likeness and oral bioavailability in determining efficacy of complement C5a antagonists V Seow, J Lim, AJ Cotterell, MK Yau, W Xu, RJ Lohman, WM Kok, ... Scientific reports 6 (1), 24575, 2016 | 45 | 2016 |
| A Patent Review on SARS Coronavirus Main Protease (3CLpro) Inhibitors CSB Chia, W Xu, P Shuyi Ng ChemMedChem 17 (1), e202100576, 2022 | 31 | 2022 |
| Novel non-peptide β-secretase inhibitors derived from structure-based virtual screening and bioassay W Xu, G Chen, OW Liew, Z Zuo, H Jiang, W Zhu Bioorganic & medicinal chemistry letters 19 (12), 3188-3192, 2009 | 30 | 2009 |
| Identification of a sub-micromolar, non-peptide inhibitor of β-secretase with low neural cytotoxicity through in silico screening W Xu, G Chen, W Zhu, Z Zuo Bioorganic & medicinal chemistry letters 20 (19), 5763-5766, 2010 | 27 | 2010 |
| Potent small agonists of protease activated receptor 2 MK Yau, JY Suen, W Xu, J Lim, L Liu, MN Adams, Y He, JD Hooper, ... ACS medicinal chemistry letters 7 (1), 105-110, 2016 | 26 | 2016 |
| PAR2 induces ovarian cancer cell motility by merging three signalling pathways to transactivate EGFR Y Jiang, J Lim, KC Wu, W Xu, JY Suen, DP Fairlie British Journal of Pharmacology 178 (4), 913-932, 2021 | 24 | 2021 |
| Molecular docking and structure–activity relationship studies on benzothiazole based non-peptidic BACE-1 inhibitors W Xu, G Chen, W Zhu, Z Zuo Bioorganic & medicinal chemistry letters 20 (21), 6203-6207, 2010 | 24 | 2010 |
| Helixconstraints and amino acid substitution in GLP-1 increase cAMP and insulin secretion but not beta-arrestin 2 signaling F Plisson, TA Hill, JM Mitchell, HN Hoang, AD de Araujo, W Xu, A Cotterell, ... European Journal of Medicinal Chemistry 127, 703-714, 2017 | 23 | 2017 |
| Update on the development of MNK inhibitors as therapeutic agents W Xu, S Kannan, CS Verma, K Nacro Journal of medicinal chemistry 65 (2), 983-1007, 2021 | 22 | 2021 |
Jeffrey Y. W. MakResearch Fellow, University of Queensland, Institute for Molecular BioscienceVerified email at uq.edu.au
